These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 21145591

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Efficacy and safety of imatinib in treatment of 151 chronic myeloid leukemia patients].
    Zhou L, Wang AH, Wang L, You JH, Li JM, Shen ZX.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):13-7. PubMed ID: 18512309
    [Abstract] [Full Text] [Related]

  • 3. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
    Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, IRIS Investigators.
    N Engl J Med; 2006 Dec 07; 355(23):2408-17. PubMed ID: 17151364
    [Abstract] [Full Text] [Related]

  • 4. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP, International Randomised Study of Interferon versus STI571 (IRIS) Study Group.
    N Engl J Med; 2003 Oct 09; 349(15):1423-32. PubMed ID: 14534335
    [Abstract] [Full Text] [Related]

  • 5. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
    de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, Szydlo R, Olavarria E, Kaeda J, Goldman JM, Marin D.
    J Clin Oncol; 2008 Jul 10; 26(20):3358-63. PubMed ID: 18519952
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H.
    Clin Cancer Res; 2005 May 01; 11(9):3425-32. PubMed ID: 15867244
    [Abstract] [Full Text] [Related]

  • 8. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
    Johnson JR, Bross P, Cohen M, Rothmann M, Chen G, Zajicek A, Gobburu J, Rahman A, Staten A, Pazdur R.
    Clin Cancer Res; 2003 Jun 01; 9(6):1972-9. PubMed ID: 12796358
    [Abstract] [Full Text] [Related]

  • 9. Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up.
    Qin Y, Jiang B, Jiang Q, Jiang H, Li J, Zhang Y, Zhu H, Li L, Chen S, Liu Y, Huang X.
    Ann Hematol; 2009 Jan 01; 88(1):37-41. PubMed ID: 18651143
    [Abstract] [Full Text] [Related]

  • 10. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A.
    Cancer; 2005 Apr 15; 103(8):1659-69. PubMed ID: 15747376
    [Abstract] [Full Text] [Related]

  • 11. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
    Koh Y, Kim I, Yoon SS, Kim BK, Kim DY, Lee JH, Lee KH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Chung J, Shin HJ, Kim SH, Kim CS, Song HS, Kim MK, Hyun MS, Ahn JS, Jung CW, Park S, Korean Society of Hematology CML working party.
    Ann Hematol; 2010 Jul 15; 89(7):725-31. PubMed ID: 20179930
    [Abstract] [Full Text] [Related]

  • 12. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M.
    Cancer; 2003 Dec 15; 98(12):2636-42. PubMed ID: 14669283
    [Abstract] [Full Text] [Related]

  • 13. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
    Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J.
    Cancer; 2008 Feb 15; 112(4):837-45. PubMed ID: 18085610
    [Abstract] [Full Text] [Related]

  • 14. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Kantarjian H.
    Cancer; 2003 Sep 15; 98(6):1105-13. PubMed ID: 12973833
    [Abstract] [Full Text] [Related]

  • 15. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D, Testoni N, Abruzzese E, Montefusco E, Ottaviani E, Iuliano F, Russo D, Gobbi M, Alimena G, Martino B, Terragna C, Pane F, Saglio G, Baccarani M, Martinelli G.
    J Clin Oncol; 2006 Jan 20; 24(3):454-9. PubMed ID: 16421422
    [Abstract] [Full Text] [Related]

  • 16. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A, Prasad K.
    J Assoc Physicians India; 2007 Feb 20; 55():109-13. PubMed ID: 17571739
    [Abstract] [Full Text] [Related]

  • 17. The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.
    Piazza RG, Magistroni V, Franceschino A, Andreoni F, Tornaghi L, Colnaghi F, Corneo G, Pogliani EM, Gambacorti-Passerini C.
    Blood Cells Mol Dis; 2006 Feb 20; 37(2):111-5. PubMed ID: 16908206
    [Abstract] [Full Text] [Related]

  • 18. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ, Ruan GR, Liu YR, Li JL, Fu JY, Wang H, Chang Y, Jiang B, Jiang Q, Jiang H, Qiu JY, Chen SS, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 20; 26(1):1-5. PubMed ID: 15946498
    [Abstract] [Full Text] [Related]

  • 19. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
    Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K, Hughes T.
    Clin Cancer Res; 2007 Dec 01; 13(23):7080-5. PubMed ID: 18056186
    [Abstract] [Full Text] [Related]

  • 20. [Therapeutic effects of imatinib on chronic myeloid leukemia in different phases and the factors affecting the effects].
    Zou WY, Xu DR, Su C, Li J, Luo SK.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug 01; 28(9):1660-2. PubMed ID: 18819894
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.